A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer.

Trial Profile

A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents and Young Adults With Treatment Refractory Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Ewing's sarcoma; Hodgkin's disease; Malignant melanoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 24 Jan 2012 Planned number of patients changed from 38 to 34 as reported by ClinicalTrials.gov (NCT01445379).
    • 24 Jan 2012 Planned number of patients changed from 38 to 34 as reported by ClinicalTrials.gov (NCT01445379).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top